Genentech gets gluey, paying $47M upfront to Orionis for degrader discovery deal

In its sec­ond deal an­nounced Wednes­day morn­ing, Roche’s Genen­tech is sign­ing up with Ori­o­n­is Bio­sciences for a mol­e­c­u­lar glue part­ner­ship in can­cer and neu­rode­gen­er­a­tion. Genen­tech will pay Ori­o­n­is $47 mil­lion up­front, and it’s promised over $2 bil­lion in po­ten­tial…#roche #genentech #orionis #boston #unlock

Source: Reuters: Health - September 20, 2023 Category: Consumer Health News Source Type: news